Purpose of the development: For the treatment of multidrug-resistant tuberculosis.

Recommended application field: Medicine.

Advantages over analogues: The test compounds showed high activity against all resistant strains of Mucobacterium tibersilus.

The development stage readiness: Tested experimental exploitation order

Description of the development:
()
Aminoacyl-tRNA synthetase (ARCase) have significant structural differences in prokaryotes and eukaryotes, which is important for the development of inhibitors that will selectively act on bacterial APCases and not affect human enzymes. With the help of computer modeling and biochemical testing methods, two chemical classes of leucyl-tRNA synthetase (LeuPS) inhibitors have been found: Mucobacterium tibersilus. The results were published in 2016 in the International Refereed Magazines of Viorogapis Apd Medikan Szetistra and Jornal of Enzoote Hippidung und Medikan Sethistra.

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Realization of finished commodity
Joint production, sale, exploitation

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua